Why the study?
Does amlodipine/benazepril combination therapy improve arterial stiffness and left ventricular hypertrophy more effectively than component monotherapy in patients with mild to moderate hypertension?
Does amlodipine/benazepril combination therapy improve arterial stiffness and left ventricular hypertrophy more effectively than component monotherapy in patients with mild to moderate hypertension?
Low-dose amlodipine/benazepril combination therapy provides greater improvements in arterial stiffness and left ventricular hypertrophy than higher-dose component monotherapies, despite similar blood pressure reductions.
Answers are grounded in this paper and cite their sources.
Favors low-dose amlodipine/benazepril over higher-dose monotherapies for arterial stiffness in hypertension; extends evidence beyond equivalent BP reduction.
Angiotensin converting enzyme (ACE) inhibitor therapy provides improvement in cardiovascular structure beyond its effect on blood pressure (BP), though intensive BP reduction is well-known to positively alter the course of cardiovascular disease. A prospective, randomized, open label, blinded endpoint, parallel group study compared the efficacy of amlodipine and benazepril monotherapies and combination therapy in patients with mild-to-moderate hypertension to determine whether the use of a vascular protective agent, an antihypertensive agent, or a combination of both, was most effective in improving cardiovascular structure and function. Patients with a seated diastolic blood pressure (DBP) of 95-114 mm Hg and a mean 24-hour ambulatory DBP of >85 mm Hg (N=106) were randomized to either amlodipine 10 mg, benazepril 40 mg, or the low-dose combination of amlodipine/benazepril 5/20 mg for 26 weeks. Twenty-four hour ambulatory BP monitoring, 24-hour ambulatory arterial compliance and echocardiograph with Doppler were performed at the end of the run-in period and active transfer period. Significant BP reductions were obtained by all three regimens. The reduction in BP was similar in patients treated with amlodipine/benazepril combination (-19.2 + 8.2/-11.4 + 5.9 mm Hg) and amlodpine monotherapy (-16.7 + 9.2/-11.6 + 5.3 mm Hg); slightly less for patients treated with benazepril monotherapy (-13.9 + 11.2/-8.6 + 7.2). Patients treated with amlodipine/benazepril combination therapy had significantly greater improvement in arterial stiffness than those who received amlodipine monotherapy (0.710 + 0.507 vs.0.284 + 0.689 % ml/ mmHg; P= 0.008) and benazepril monotherapy (0.710 + 0.507 vs.0.284 + 0.689 % ml/ mmHg; P= 0.008). All three agents resulted in significant reduction of left ventricular hypertrophy compared to baseline levels, with combination therapy resulting in significantly greater regression than amlodipine monotherapy and numerically greater regression than benazepril monotherapy. Despite similar reductions in BP observed by all three regimens, changes in cardiovascular structure and function were significantly greater in patients treated with the amlodipine/benazepril combination, suggesting that maximal cardiovascular protection is achieved by combining a BP reduction agent such as a CCB, with a vascular protective agent, such as an ACE inhibitor.
No takes yet. Share an insight, caveat, or question.
J NEUTEL (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: